Nasdaq

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia ...
Yahoo Finance

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England ...

STAMFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...
Yahoo Finance

Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica

STAMFORD, Conn., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to ...
EurekAlert!

New formulation of FDA-approved drug shows encouraging results for treating a common itch condition

New York, NY (February 8, 2023) – Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no ...
Mena FN

Cara Therapeutics Announces Positive Topline Results From KOMFORT Phase 2 Trial Of Oral Difelikefalin For The Treatment Of Pruritus In Patients With Notalgia Paresthetica

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical ...